Targeted Optical Imaging and Photodynamic Therapy

  • N. Solban
  • B. Ortel
  • B. Pogue
  • T. Hasan
Conference paper
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 49)

12.7 Conclusion

This review of photodiagnosis and phototherapy is a summary of specific aspects of optical targeting. It is not meant to be a comprehensive review, rather it is expected to serve both as an introduction of the approach for an audience outside the field of optical technologies. As such it is somewhat subjective and it is important for the reader to be aware that this is a very brief summary of literature and concepts in a rapidly emerging field. With the advent of new molecular probes and light delivery and light capturing techniques, it is likely that the field of optical treatment and diagnosis will have developed to such an extent in the next 5 years so as to make this writing irrelevant!

Many of the PS described throughout this chapter are potentially useful for both diagnosis and therapy. The fluorescence produced by these compounds may be exploited for several purposes: the identification and delineation of malignant tissues, the quantification of PS at the tumor site, and potentially the monitoring of oxygen and PS consumption during therapeutic light exposure. In an optimal scenario, targeted delivery identifies diseased tissue and in the same procedure treatment is delivered. A targeting molecule (MAb or peptide based) would deliver an optically activable agent specifically to tumors. This OAA would be used for diagnosis and treatment. The progressive improvement of remote imaging devices and molecular targeting strategies make this an attractive aim of preclinical and clinical development.


Photodynamic Therapy Fluence Rate Cheek Pouch PpIX Fluorescence Light Dosimetry 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Achilefu S, Srinivasan A, Schmidt MA, Jimenez HN, Bugaj JE, Erion JL (2003) Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors. J MedChem 46:3403–3411Google Scholar
  2. Akhlynina TV, Rosenkranz AA, Jans DA, Sobolev AS (1995) Insulin-mediated intracellular targeting enhances the photodynamic activity of chlorin e6. Cancer Res 55:1014–1019PubMedGoogle Scholar
  3. Allison BA, Pritchard PH, Levy JG (1994) Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br J Cancer 69:833–839PubMedGoogle Scholar
  4. Barel A, Jori G, Perin A, Romandini P, Pagnan A, Biffanti S (1986) Role of high-, low-and very low-density lipoproteins in the transport and tumor-delivery of hematoporphyrin in vivo. Cancer Lett 32:145–150PubMedCrossRefGoogle Scholar
  5. Baumgartner R, Huber RM, Schulz H, Stepp H, Rick K, Gamarra F, Leberig A, Roth C (1996) Inhalation of 5-aminolevulinic acid: a new technique for fluorescence detection of early stage lung cancer. J Photochem Photo-biol B 36:169–174CrossRefGoogle Scholar
  6. Bigio IJ, Mourant JR, Los G (1999) Noninvasive, in-situ measurement of drug concentrations in tissue using optical spectroscopy. J Gravit Physiol 6:P173–175PubMedGoogle Scholar
  7. Braichotte DR, Savary JF, Monnier P, van den Bergh HE (1996) Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of the esophagus using fluorescence spectroscopy. Lasers Surg Med 19:340–346PubMedCrossRefGoogle Scholar
  8. Bugaj JE, Achilefu S, Dorshow RB, Rajagopalan R (2001) Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. J Biomed Opt 6:122–133PubMedCrossRefGoogle Scholar
  9. Cahalan MD, Parker I, Wei SH, Miller MJ (2002) Two-photon tissue imaging: seeing the immune system in a fresh light. Nat Rev Immunol 2:872–880PubMedCrossRefGoogle Scholar
  10. Casas A, Batlle A (2002) Rational design of 5-aminolevulinic acid derivatives aimed at improving photodynamic therapy. Curr Med Chem Anti-Canc Agents 2:465–475CrossRefGoogle Scholar
  11. Cavanaugh PG (2002) Synthesis of chlorin e6-transferrin and demonstration of its light-dependent in vitro breast cancer cell killing ability. Breast Cancer Res Treat 72:117–130PubMedCrossRefGoogle Scholar
  12. Cernay T, Zimmermann HW (1996) Selective photosensitization of mitochondria by the lipophilic cationic porphyrin POR10. J Photochem Photobiol B 34:191–196PubMedCrossRefGoogle Scholar
  13. Chowdhary RK, Shariff I, Dolphin D (2003) Drug release characteristics of lipid based benzoporphyrin derivative. J Pharm Sci 6:13–19Google Scholar
  14. Cincotta L, Foley JW, MacEachern T, Lampros E, Cincotta AH (1994) Novel photodynamic effects of a benzophenothiazine on two different murine sarcomas. Cancer Res 54:1249–1258PubMedGoogle Scholar
  15. Cincotta L, Szeto D, Lampros E, Hasan T, Cincotta AH (1996) Benzophenothiazine and benzoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas. Photochem Photobiol 63:229–237PubMedCrossRefGoogle Scholar
  16. Dummin H, Cernay T, Zimmermann HW (1997) Selective photosensitization of mitochondria in HeLa cells by cationic Zn (II) phthalocyanines with lipophilic side-chains. J Photochem Photobiol B 37:219–229PubMedCrossRefGoogle Scholar
  17. Fingar VH, Taber SW, Haydon PS, Harrison LT, Kempf SJ, Wieman TJ (2000) Vascular damage after photodynamic therapy of solid tumors: a view and comparison of effect in pre-clinical and clinical models at the University of Louisville. In Vivo 14:93–100PubMedGoogle Scholar
  18. Freitas I (1990) Lipid accumulation: the common feature to photosensitizer-retaining normal and malignant tissues. J Photochem Photobiol B 7:359–361PubMedCrossRefGoogle Scholar
  19. Friesen SA, Hjortland GO, Madsen SJ, Hirschberg H, Engebraten O, Nesland JM, Peng Q (2002) 5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review). Int J Oncol 21:577–582PubMedGoogle Scholar
  20. Frisoli JK, Tudor EG, Flotte TJ, Hasan T, Deutsch TF, Schomacker KT (1993) Pharmacokinetics of a fluorescent drug using laser-induced fluorescence. Cancer Res 53:5954–5961PubMedGoogle Scholar
  21. Fritsch C, Lang K, Neuse W, Ruzicka T, Lehmann P (1998) Photodynamic diagnosis and therapy in dermatology. Skin Pharmacol Appl Skin Physiol 11:358–373PubMedCrossRefGoogle Scholar
  22. Fulljames C, Stone N, Bennett D, Barr H (1999) Beyond white light endoscopy — the prospect for endoscopic optical biopsy. Ital J Gastroenterol Hepatol 31:695–704PubMedGoogle Scholar
  23. Gijsens A, Missiaen L, Merlevede W, de Witte P (2000) Epidermal growth factor-mediated targeting of chlorin e6 selectively potentiates its photodynamic activity. Cancer Res 60:2197–2202PubMedGoogle Scholar
  24. Granville DJ, Cassidy BA, Ruehlmann DO, Choy JC, Brenner C, Kroemer G, van Breemen C, Margaron P, Hunt DW, McManus BM (2001) Mitochondrial release of apoptosis-inducing factor and cytochrome c during smooth muscle cell apoptosis. Am J Pathol 159:305–311PubMedGoogle Scholar
  25. Guimond M, Balassy A, Barrette M, Brochu S, Perreault C, Roy DC (2002) P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells. Blood 100:375–382PubMedCrossRefGoogle Scholar
  26. Gupta S (1995) P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy. Drugs Aging 7:19–29PubMedCrossRefGoogle Scholar
  27. Hadjantonakis AK, Nagy A (2001) The color of mice: in the light of GFP-variant reporters. Histochem Cell Biol 115:49–58PubMedGoogle Scholar
  28. Hamblin MR, Tawakol A, Castano PA, Gad F, Zahra T, Ahmad A, Stern J, Ortel B, Chirico S, Shirazi A, Syed S, Muller JE (2003) Macrophage-targeted photodynamic detection of vulnerable atherosclerotic plaque. Proc SPIE (in press)Google Scholar
  29. Hasan T, Lin CW, Lin A (1989) Laser-induced selective cytotoxicity using monoclonal antibody-chromophore conjugates. Prog Clin Biol Res 288: 471–477PubMedGoogle Scholar
  30. Hasan T, Ortel B, Moor A, Pogue B (2003) Photodynamic therapy of cancer. In: Kufe DW, Pollack RE, Weichselbaum RR, et al. (eds) Cancer Medicine, 6th edn. B.C. Decker Hamilton, Ontario, pp 605–622Google Scholar
  31. Hawrysz DJ, Sevick-Muraca EM (2000) Developments toward diagnostic breast cancer imaging using near-infrared optical measurements and fluorescent contrast agents. Neoplasia 2:388–417PubMedCrossRefGoogle Scholar
  32. Hunt DW, Chan AH (2000) Influence of photodynamic therapy on immunological aspects of disease — an update. Expert Opin Investig Drugs 9: 807–817PubMedCrossRefGoogle Scholar
  33. Iinuma S, Schomacker KT, Wagnieres G, Rajadhyaksha M, Bamberg M, Momma T, Hasan T (1999) In vivo fluence rate and fractionation effects on tumor response and photobleaching: photodynamic therapy with two photosensitizers in an orthotopic rat tumor model. Cancer Res 59:6164–6170PubMedGoogle Scholar
  34. Jiang FN, Jiang S, Liu D, Richter A, Levy JG (1990) Development of technology for linking photosensitizers to a model monoclonal antibody. J Immunol Methods 134:139–149PubMedCrossRefGoogle Scholar
  35. Kennedy JC, Marcus SL, Pottier RH (1996) Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. J Clin Laser Med Surg 14:289–304PubMedGoogle Scholar
  36. Kessel D (1992) The role of low-density lipoprotein in the biodistribution of photosensitizing agents. J Photochem Photobiol B 14:261–262PubMedCrossRefGoogle Scholar
  37. Kessel D, Luo Y (1998) Mitochondrial photodamage and PDT-induced apoptosis. J Photochem Photobiol B 42:89–95PubMedCrossRefGoogle Scholar
  38. Kessel D, Luo Y (1999) Photodynamic therapy: a mitochondrial inducer of apoptosis. Cell Death Differ 6:28–35PubMedCrossRefGoogle Scholar
  39. Kessel D, Woodburn K, Gomer CJ, Jagerovic N, Smith KM (1995 a) Photosensitization with derivatives of chlorin p6. J Photochem Photobiol B 28:13–18PubMedCrossRefGoogle Scholar
  40. Kessel D, Woodburn K, Henderson BW, Chang CK (1995 b) Sites of photodamage in vivo and in vitro by a cationic porphyrin. Photochem Photobiol 62:875–881PubMedGoogle Scholar
  41. Konan YN, Gurny R, Allemann E (2002) State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B 66:89–106PubMedCrossRefGoogle Scholar
  42. Lee CC, Pogue BW, Burke GC, Hoopes PJ (2003) Spatial heterogeneity and temporal kinetics of photosensitizer (AlPcS2) concentration in murine tumors RIF-1 and MTG-B. Photochem Photobiol Sci 2:145–150PubMedCrossRefGoogle Scholar
  43. Lee CC, Pogue BW, Strawbridge RR, Moodie KL, Bartholomew LR, Burke GC, Hoopes PJ (2001) Comparison of photosensitizer (AIPcS2) quantification techniques: in situ fluorescence microsampling versus tissue chemical extraction. Photochem Photobiol 74:453–460PubMedCrossRefGoogle Scholar
  44. Leunig A, Betz CS, Mehlmann M, Stepp H, Arbogast S, Grevers G, Baum-gartner R (2000) Detection of squamous cell carcinoma of the oral cavity by imaging 5-aminolevulinic acid-induced protoporphyrin IX fluorescence. Laryngoscope 110:78–83PubMedCrossRefGoogle Scholar
  45. Liang C, Sung KB, Richards-Kortum RR, Descour MR (2002) Design of a high-numerical-aperture miniature microscope objective for an endoscopic fiber confocal reflectance microscope. Appl Opt 41:4603–4610PubMedCrossRefGoogle Scholar
  46. Marcus SL, Sobel RS, Golub AL, Carroll RL, Lundahl S, Shulman DG (1996) Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status. J Clin Laser Med Surg 14:59–66PubMedGoogle Scholar
  47. Marijnissen JP, Star WM, in’t Zandt HJ, D’Hallewin MA, Baert L (1993) In situ light dosimetry during whole bladder wall photodynamic therapy: clinical results and experimental verification. Phys Med Biol 38:567–582PubMedCrossRefGoogle Scholar
  48. Marti A, Jichlinski P, Lange N, Ballini JP, Guillou L, Leisinger HJ, Kucera P (2003) Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol 170:428–432PubMedCrossRefGoogle Scholar
  49. Mathupala SP, Rempel A, Pedersen PL (1997) Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 29:339–343PubMedCrossRefGoogle Scholar
  50. Messmann H (2000) 5-Aminolevulinic acid-induced protoporphyrin IX for the detection of gastrointestinal dysplasia. Gastrointest Endosc Clin N Am 10:497–512PubMedGoogle Scholar
  51. Moan J, Berg K (1991) The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 53:549–553PubMedCrossRefGoogle Scholar
  52. Murray JM (1992) Neuropathology in depth: the role of confocal microscopy. J Neuropath Exp Neurol 51:475–487PubMedCrossRefGoogle Scholar
  53. Nelson JS, Liaw LH, Orenstein A, Roberts WG, Berns MW (1988) Mechanism of tumor destruction following photodynamic therapy with hematoporphyrin derivative, chlorin, and phthalocyanine. J Natl Cancer Inst 80:1599–1605PubMedCrossRefGoogle Scholar
  54. Ntziachristos V, Bremer C, Weissleder R (2003) Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol 13:195–208PubMedGoogle Scholar
  55. Ntziachristos V, Tung CH, Bremer C, Weissleder R (2002) Fluorescence molecular tomography resolves protease activity in vivo. Nat Med 8:757–760PubMedCrossRefGoogle Scholar
  56. Oenbrink G, Jurgenlimke P, Gabel D (1988) Accumulation of porphyrins in cells: influence of hydrophobicity aggregation and protein binding. Photochem Photobiol 48:451–456PubMedCrossRefGoogle Scholar
  57. Patterson MS, Wilson BC, Graff R (1990a) In vivo tests of the concept of photodynamic threshold dose in normal rat liver photosensitized by aluminum chlorosulphonated phthalocyanine. Photochem Photobiol 51:343–349PubMedCrossRefGoogle Scholar
  58. Patterson MS, Wilson BC, Wyman DR (1990b) The propagation of optical radiation in tissue I. Models of radiation transport and their application. Lasers Med Sci 6:155–168CrossRefGoogle Scholar
  59. Patterson MS, Wilson BC, Wyman DR (1990c) The propagation of optical radiation in tissue II. Optical properties of tissues and resulting fluence distributions. Lasers Med Sci 6:379–390CrossRefGoogle Scholar
  60. Pogue BW, Hasan T (2003) Targeting in photodynamic therapy and photo-imaging. OPN 14:36–43Google Scholar
  61. Pogue BW, Burke GC (1998) Fiber optic bundle design for quantitative fluorescence measurement from tissue. Appl Opt 37:7429–7436PubMedCrossRefGoogle Scholar
  62. Pogue BW, Poplack SP, McBride TO, Wells WA, Osterman KS, Osterberg UL, Paulsen KD (2001) Quantitative hemoglobin tomography with diffuse near-infrared spectroscopy: pilot results in the breast. Radiology 218:261–266PubMedGoogle Scholar
  63. Polo L, Valduga G, Jori G, Reddi E (2002) Low-density lipoprotein receptors in the uptake of tumour photosensitizers by human and rat transformed fibroblasts. Int J Biochem Cell Biol 34:10–23PubMedCrossRefGoogle Scholar
  64. Rahimipour S, Ben-Aroya N, Ziv K, Chen A, Fridkin M, Koch Y (2003) Receptor-mediated targeting of a photosensitizer by its conjugation to gonadotropin-releasing hormone analogues. J Med Chem 46:3965–3974PubMedCrossRefGoogle Scholar
  65. Richter AM, Waterfield E, Jain AK, Canaan AJ, Allison BA, Levy JG (1993) Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model. Photochem Photobiol 57:1000–1006PubMedCrossRefGoogle Scholar
  66. Riedl CR, Daniltchenko D, Koenig F, Simak R, Loening SA, Pflueger H (2001) Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 165:1121–1123PubMedCrossRefGoogle Scholar
  67. Riedl CR, Plas E, Pfluger H (1999) Fluorescence detection of bladder tumors with 5-amino-levulinic acid. J Endourol 13:755–759PubMedCrossRefGoogle Scholar
  68. Sakaeda T, Nakamura T, Okumura K (2003) Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4:397–410PubMedCrossRefGoogle Scholar
  69. Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R (1994) Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 101:1953–1961PubMedGoogle Scholar
  70. Shin DM, Gimenez IB, Lee JS, Nishioka K, Wargovich MJ, Thacher S, Lotan R, Slaga TJ, Hong WK (1990) Expression of epidermal growth factor receptor, polyamine levels, ornithine decarboxylase activity, micronuclei, and transglutaminase I in a 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch carcinogenesis model. Cancer Res 50:2505–2510PubMedGoogle Scholar
  71. Sitnik TM, Hampton JA, Henderson BW (1998) Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. Br J Cancer 77:1386–1394PubMedGoogle Scholar
  72. Sitnik TM, Henderson BW (1998) The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy. Photochem Photobiol 67:462–466PubMedCrossRefGoogle Scholar
  73. Soukos NS, Hamblin MR, Keel S, Fabian RL, Deutsch TF, Hasan T (2001) Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res 61:4490–4496PubMedGoogle Scholar
  74. Stolz B, Weckbecker G, Smith-Jones PM, Albert R, Raulf F, Bruns C (1998) The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhel, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med 25:668–674PubMedCrossRefGoogle Scholar
  75. Taroni P, Pifferi A, Torricelli A, Comelli D, Cubeddu R (2003) In vivo absorption and scattering spectroscopy of biological tissues. Photochem Photobiol Sci 2:124–129PubMedCrossRefGoogle Scholar
  76. Utzinger U, Richards-Kortum RR (2003) Fiber optic probes for biomedical optical spectroscopy. J Biomed Optics 8:121–147CrossRefGoogle Scholar
  77. Vrouenraets MB, Visser GW, Loup C, Meunier B, Stigter M, Oppelaar H, Stewart FA, Snow GB, van Dongen GA (2000) Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: A new possibility for use in photodynamic therapy. Int J Cancer 88:108–114PubMedCrossRefGoogle Scholar
  78. Vrouenraets MB, Visser GW, Stigter M, Oppelaar H, Snow GB, van Dongen GA (2001) Targeting of aluminum (III) phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: improved efficacy in photo-dynamic therapy. Cancer Res 61:1970–1975PubMedGoogle Scholar
  79. Vulcan TG, Zhu TC, Rodriguez CE, Hsi A, Fraker DL, Baas P, Murrer LH, Star WM, Glatstein E, Yodh AG, Hahn SM (2000) Comparison between isotropic and nonisotropic dosimetry systems during intraperitoneal photo-dynamic therapy. Lasers Surg Med 26:292–301PubMedCrossRefGoogle Scholar
  80. Wagnieres GA, Star WM, Wilson BC (1998) In vivo fluorescence spectroscopy and imaging for oncological applications. Photochem Photobiol 68:603–632PubMedGoogle Scholar
  81. Wilson BC, Patterson MS, Lilge L (1997) Implicit and explicit dosimetry in photodynamic therapy: a new paradigm. Lasers Med Sci 12:182–199CrossRefGoogle Scholar
  82. Wood SR, Holroyd JA, Brown SB (1997) The subcellular localization of Zn(II) phthalocyanines and their redistribution on exposure to light. Photochem Photobiol 65:397–402PubMedCrossRefGoogle Scholar
  83. Yarmush ML, Thorpe WP, Strong L, Rakestraw SL, Toner M, Tompkins RG (1993) Antibody targeted photolysis. Crit Rev Ther Drug Carrier Syst 10:197–252PubMedGoogle Scholar
  84. Zhang M, Zhang Z, Blessington D, Li H, Busch TM, Madrak V, Miles J, Chance B, Glickson JD, Zheng G (2003) Pyropheophorbide 2-deoxyglucosamide: a new photosensitizer targeting glucose transporters. Bioconjug Chem 14:709–714PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • N. Solban
    • 1
  • B. Ortel
    • 1
  • B. Pogue
    • 1
    • 2
  • T. Hasan
    • 3
  1. 1.Wellman Laboratories of Photomedicine, Department of Dermatology, Massachusetts General HospitalHarvard Medical SchoolBostonUSA
  2. 2.Thayer School of EngineeringDartmouth CollegeHanoverUSA
  3. 3.Wellmann Laboratories of PhotomedicineHarvard Medical School Massachusetts General HospitalBostonUSA

Personalised recommendations